PEN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PE

Mkt Cap

$12.64B

Volume

246.69K

Next Earnings

November 4th

Loading chart

PE

PENPenumbra, Inc.

PEN

Pay with—

Available Balance0.00

PE

Mkt Cap

$12.64B

Volume

246.69K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

IART vs. PEN: Which Stock Is the Better Value Option?In a comparison of two medical instruments sector stocks, Integra LifeSciences (IART) emerges as the better value opportunity for investors compared to Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.62 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.18 and Value grade of D. IART's superior valuation metrics and improving earnings outlook make it the more attractive choice for value investors.Zacks Investment Research · Oct 1, 2026

IART or PEN: Which Is the Better Value Stock Right Now?A comparison of two medical instruments companies reveals that Integra LifeSciences (IART) presents a more attractive value opportunity than Penumbra (PEN). IART has a Zacks Rank of #2 (Buy) with a forward P/E of 6.61 and Value grade of B, while PEN has a Zacks Rank of #3 (Hold) with a forward P/E of 64.35 and Value grade of D. IART's stronger earnings estimate revisions and superior valuation metrics make it the preferred choice for value investors.Zacks Investment Research · Sep 29, 2026

Reasons to Retain Penumbra Stock in Your Portfolio for NowPenumbra (PEN) reported Q2 2026 revenues up 14.9% driven by thrombectomy and embolization products, with international sales growing 7.6% across 100+ countries. However, SG&A expenses grew faster than revenues at 24.1%, causing operating margins to compress. Foreign exchange exposure and macroeconomic sensitivity pose risks, though the company maintains a Zacks Rank #3 (Buy) rating with shares up 21.1% over the past year.Zacks Investment Research · Sep 16, 2026

Incuvate Files Patent Infringement Lawsuit Against PenumbraIncuvate has filed a patent-infringement lawsuit against Penumbra in U.S. District Court for the Northern District of California, alleging that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System and related components infringe five Incuvate patents covering real-time aspiration monitoring technology. Incuvate is seeking damages, injunctive relief, and other remedies.GlobeNewswire Inc. · Aug 25, 2026

GuideAI Health Appoints Renowned Interventional Radiologist Dr. James Benenati to Advisory Board Following FDA 510(k) Clearance of VAOTGuideAI Health Corp. announced the appointment of renowned interventional radiologist Dr. James Benenati, Chief Medical Officer of Penumbra Inc., to its Advisory Board following FDA 510(k) clearance of its VAOT software. VAOT is an AI-based triage tool designed to assist radiologists in identifying peripheral arterial disease and vascular occlusion in the lower extremities to enable earlier diagnosis and intervention.GlobeNewswire Inc. · Jul 6, 2026

Microcatheter Market Size to Reach USD 1.79 Billion by 2035 | SNS InsiderThe global microcatheter market is valued at USD 1.05 billion in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 5.53%. Growth is driven by increasing adoption of minimally invasive cardiovascular and neurovascular procedures, rising prevalence of cardiovascular and neurovascular disorders, and advancements in catheter technologies. Aspiration microcatheters lead with 36% market share, while steerable microcatheters are the fastest-growing segment. North America dominates with 34% of global revenues, with Asia-Pacific emerging as the fastest-growing region.GlobeNewswire Inc. · Jun 19, 2026

ServisFirst Gets Axed by Champlain — a Minor Position in a Major DrawdownChamplain Investment Partners completely exited its position in ServisFirst Bancshares, selling 1.57 million shares worth approximately $124.23 million. However, the exit appears to be part of broader fund downsizing rather than a targeted judgment on the company, as Champlain's reportable AUM contracted by roughly $2 billion quarter-over-quarter. The position represented only 1.14% of the fund's prior-quarter holdings.The Motley Fool · May 17, 2026

3 Reasons Boston Scientific Stock Could Quietly 5X as the World AgesBoston Scientific is well-positioned to capitalize on global aging demographics, with products addressing age-related conditions like atrial fibrillation, chronic pain, and Parkinson's disease. Recent acquisitions of Penumbra and Silk Road Medical expand its stroke treatment capabilities. Despite strong fundamentals and double-digit growth, the stock has been beaten down following conservative 2026 guidance, creating a potentially attractive valuation opportunity.The Motley Fool · Mar 5, 2026

Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s InvestigationsInvestor rights law firm Halper Sadeh LLC is investigating four companies for potential federal securities law violations and breaches of fiduciary duties related to their merger or acquisition transactions. The firm is seeking increased consideration for shareholders and additional disclosures regarding the proposed deals.GlobeNewswire Inc. · Feb 2, 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--PEN, RAPT, NATH, and LSTAMonteverde & Associates PC, a class action law firm, is investigating four merger transactions: Penumbra's sale to Boston Scientific, RAPT Therapeutics' sale to GSK, Nathan's Famous' sale to Smithfield Foods, and Lisata Therapeutics' sale to Smithfield Foods. The firm is seeking shareholders who may have concerns about these deals.Benzinga · Jan 28, 2026

to start trading

PE

PENPenumbra, Inc.

PEN

Pay with—

Available Balance0.00

Your PositionYou don't own any PEN yet.

Related Tickers

Earnings